Holen Sie sich die Stockscreener-App
2.74
0.91%
-0.03
Schlusskurs vom Vortag:
$2.77
Offen:
$2.77
24-Stunden-Volumen:
79,646
Relative Volume:
0.18
Marktkapitalisierung:
$215.99M
Einnahmen:
-
Nettoeinkommen (Verlust:
$-29.07M
KGV:
-8.8387
EPS:
-0.31
Netto-Cashflow:
$-31.85M
1W Leistung:
-4.02%
1M Leistung:
-18.06%
6M Leistung:
+0.55%
1J Leistung:
+112.78%
1-Tages-Spanne:
$2.73
$2.83
1-Wochen-Bereich:
$2.67
$3.07
52-Wochen-Spanne:
$0.97
$4.00
Trevi Therapeutics Inc Stock (TRVI) Company Profile
Firmenname
Trevi Therapeutics Inc
Sektor
Branche
Telefon
203-304-2499
Adresse
195 CHURCH STREET, NEW HAVEN, CT
Vergleichen Sie TRVI mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
| TRVI | 2.74 | 215.99M | 0 | -29.07M | -31.85M | -0.31 |
| VRTX | 450.00 | 115.43B | 10.63B | -479.80M | -1.35B | 13.33 |
| REGN | 748.66 | 82.04B | 13.85B | 4.65B | 3.32B | 35.06 |
| ARGX | 588.46 | 35.30B | 1.86B | -40.29M | -1.28B | -4.16 |
| ALNY | 248.13 | 32.04B | 2.09B | -332.26M | 16.06M | -4.14 |
| BNTX | 106.50 | 24.89B | 3.30B | -501.07M | 1.03B | 11.54 |
Trevi Therapeutics Inc Stock (TRVI) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2023-04-12 | Eingeleitet | B. Riley Securities | Buy |
| 2022-11-22 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | BMO Capital Markets | Outperform |
| 2019-06-03 | Eingeleitet | Needham | Buy |
| 2019-06-03 | Eingeleitet | SVB Leerink | Outperform |
| 2019-06-03 | Eingeleitet | Stifel | Buy |
Alle ansehen
Trevi Therapeutics Inc Aktie (TRVI) Neueste Nachrichten
Trevi Therapeutics to Present Haduvio Development at Piper Sandler Healthcare Conference | TRVI Stock News - StockTitan
Trevi Therapeutics to Participate in Upcoming April Events - GuruFocus.com
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $7.43 Consensus Target Price from Brokerages - Defense World
Trevi Therapeutics to Present at the Emerging Growth Conference on February 22, 2023 - Quantisnow
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives $7.43 Average PT from Brokerages - MarketBeat
How Do Things Look For Trevi Therapeutics Inc (NASDAQ: TRVI) In The Short-Term? - Stocks Register
Trevi Therapeutics Announces Proposed Public Offering - Quantisnow
Trevi Therapeutics to Participate in Upcoming September Events - Quantisnow
Trevi Therapeutics to Present at H.C. Wainwright 24th Annual Global Investment Conference - Quantisnow
Trevi Therapeutics Provides Business Update Ahead of Upcoming Conferences - Quantisnow
FY2024 Earnings Forecast for TRVI Issued By Leerink Partnrs - MarketBeat
Leerink Partnrs Has Negative Outlook of TRVI FY2024 Earnings - Defense World
Earnings call: Trevi Therapeutics reports Q3 2024 financials, clinical updates - Investing.com
Trevi Therapeutics' (TRVI) "Buy" Rating Reiterated at Needham & Company LLC - MarketBeat
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Q3 2024 Earnings Call Transcript - Insider Monkey
Earnings call: Trevi Therapeutics reports Q3 2024 financials, clinical updates By Investing.com - Investing.com UK
Trevi Therapeutics Inc (TRVI) Q3 2024 Earnings Call Highlights: - GuruFocus.com
Trevi Therapeutics Inc (TRVI) Q3 2024 Earnings Call Highlights: Navigating Increased Losses and ... - Yahoo Finance
Trevi Therapeutics Reports Q3 2024 Progress and Financials - TipRanks
Trevi Therapeutics Advances Clinical Trials Despite Widening Q3 Losses; Cash Runway Extended | TRVI Stock News - StockTitan
Rosalind Advisors Inc. Sells 641,577 Shares of Trevi Therapeutics, Inc. (NASDAQ:TRVI) - MarketBeat
Trevi Therapeutics to Report Third Quarter 2024 Financial Result - GuruFocus.com
Trevi Therapeutics (TRVI) Set to Announce Earnings on Wednesday - MarketBeat
Trevi Therapeutics to Report Third Quarter 2024 Financial Results and Provide a Corporate Update on November 6, 2024 - StreetInsider.com
Trevi Therapeutics Adds Clinical Development Expertise in Chroni - GuruFocus.com
Rosalind Advisors, Inc. Reduces Stake in Trevi Therapeutics Inc. - Yahoo Finance UK
Trevi Therapeutics shares retain buy rating on Haduvio prospects By Investing.com - Investing.com UK
Trevi Therapeutics (NASDAQ:TRVI) Given "Buy" Rating at HC Wainwright - MarketBeat
Trevi Therapeutics completes enrollment for Phase 2a trial - Investing.com
Trevi Therapeutics completes enrollment for Phase 2a trial By Investing.com - Investing.com Australia
Trevi Therapeutics, Inc. Completes Enrollment in the Phase 2A RIVER Trial of Haduvio - Marketscreener.com
Trevi Therapeutics Completes Enrollment for Phase 2a RIVER Trial in Refractory Chronic Cough - Citizentribune
Trevi Therapeutics, Inc. (NASDAQ:TRVI) Receives Consensus Recommendation of "Buy" from Analysts - MarketBeat
TSX Global Gold Index (TTGD) QuotePress Release - The Globe and Mail
Trevi Therapeutics to Participate in Upcoming Commercial and Investor Conferences - Citizentribune
Trevi Therapeutics Inc (TRVI) Q2 2024 Earnings Call Highlights: Navigating Financial Challenges ... - Yahoo Finance
Trevi Therapeutics Inc (TRVI) Q2 2024 Earnings Call Highlights: - GuruFocus.com
Oppenheimer maintains Outperform on Trevi Therapeutics on Haduvio potential By Investing.com - Investing.com Canada
Trevi Therapeutics' (TRVI) Buy Rating Reaffirmed at B. Riley - MarketBeat
Trevi Therapeutics reports progress in clinical trials - Investing.com
Trevi Therapeutics (NASDAQ:TRVI) Given "Buy" Rating at Needham & Company LLC - MarketBeat
Trevi updates on clinical progress for chronic cough treatment - The Pharma Letter
Trevi Therapeutics reports progress in clinical trials By Investing.com - Investing.com UK
Trevi Therapeutics, Inc. Announces Updates on Its Clinical Development Programs - Marketscreener.com
Trevi Therapeutics shares keep buy rating, positive trials By Investing.com - Investing.com UK
Trevi Therapeutics hits 50% enrollment in IPF cough study By Investing.com - Investing.com South Africa
Trevi Therapeutics hits 50% enrollment in IPF cough study - Investing.com India
Finanzdaten der Trevi Therapeutics Inc-Aktie (TRVI)
Umsatz
Nettogewinn
Free Cashflow
ENV
Trevi Therapeutics Inc-Aktie (TRVI) Insiderhandel
| Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
|---|---|---|---|---|---|---|---|
| GOOD JENNIFER L | President & CEO |
Sep 09 '24 |
Option Exercise |
1.43 |
1,840 |
2,631 |
215,153 |
| GOOD JENNIFER L | President & CEO |
Sep 06 '24 |
Sale |
3.03 |
4,219 |
12,784 |
213,313 |
| GOOD JENNIFER L | President & CEO |
Sep 09 '24 |
Sale |
3.04 |
1,840 |
5,587 |
213,313 |
| GOOD JENNIFER L | President & CEO |
Sep 05 '24 |
Option Exercise |
1.43 |
40,277 |
57,596 |
253,590 |
| GOOD JENNIFER L | President & CEO |
Sep 04 '24 |
Option Exercise |
1.43 |
10,981 |
15,703 |
224,294 |
| GOOD JENNIFER L | President & CEO |
Sep 03 '24 |
Option Exercise |
1.43 |
3,863 |
5,524 |
217,176 |
| GOOD JENNIFER L | President & CEO |
Sep 05 '24 |
Sale |
3.11 |
40,277 |
125,310 |
213,313 |
| GOOD JENNIFER L | President & CEO |
Sep 04 '24 |
Sale |
3.02 |
10,981 |
33,205 |
213,313 |
| GOOD JENNIFER L | President & CEO |
Sep 03 '24 |
Sale |
3.02 |
3,863 |
11,677 |
213,313 |
1.80%
0.42%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):